# FDA 483 - Chakrapani Ayurveda Clinic & Research Center - February 18, 2022

Source: https://www.keypedia.com/records/483/chakrapani-ayurveda-clinic-research-center/c907f027-0d21-4e59-ab04-047c945cb334

> FDA 483 for Chakrapani Ayurveda Clinic & Research Center on February 18, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Chakrapani Ayurveda Clinic & Research Center
- Inspection Date: 2022-02-18
- Product Type: drugs
- Office Name: Office of Biological Products Operations - Division I
- Summary: An FDA inspection of Chakrapani Ayurveda Clinic & Research Centre in Jaipur, India, revealed numerous deficiencies in their manufacturing and quality control processes for dietary supplements exported to the U.S. The firm failed to establish and follow written procedures for critical operations, including quality control, component and product specifications, and record-keeping. These issues indicate a severe lack of control over product quality, purity, and strength, raising concerns about the safety and compliance of their dietary supplements.

## Related Officers

- [Kunapuli T. Madhusudhan](https://www.keypedia.com/people/kunapuli-t-madhusudhan/24f3d229-0d99-4bb3-bf3b-738ca48c9d3c)

Company: https://www.keypedia.com/companies/chakrapani-ayurveda-clinic-research-center/1796ffef-3202-45b5-9c18-fbc3a2b8005a

Office: https://www.keypedia.com/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1